Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Follow us on Twitter

  • The Food and Drug Administration has authorized a clinical trial of stem cells extracted and cultured from patients… https://t.co/68QuQj2ik5
    about 9 hours ago
  • New post on Science and Enterprise: FDA Clears Stem Cell Trial for Multiple Sclerosis https://t.co/iLohWcDKEC #Science #Business
    about 9 hours ago
  • A venture philanthropy group is funding an initiative to find digital data indicators of early onset of Alzheimer's… https://t.co/YBoAZKBjBw
    about 1 day ago
  • New post on Science and Enterprise: Alzheimer’s Digital Biomarkers Project Gains New Funds https://t.co/lxhfwd4Bzi #Science #Business
    about 1 day ago
  • Shionogi starts clinical test on oral COVID drug | NHK WORLD-JAPAN News https://t.co/EAQvk9nGjw
    about 2 days ago

Please share Science & Enterprise

GSK, Biotech Partner on Neuro Antibodies in $2.2B Deal

Brain activity graphic

GlaxoSmithKline and biotechnology company Alector Inc. agreed to co-develop two synthetic antibodies for treating neurodegenerative disorders. . . . → Read More: GSK, Biotech Partner on Neuro Antibodies in $2.2B Deal

Microbiome Drug Candidate Licensed in $525M Deal

C. difficile in petri dish

A therapy designed to regenerate healthy gut microbes for treating dangerous intestinal infections is licensed for commercialization to Nestlé Health Science. . . . → Read More: Microbiome Drug Candidate Licensed in $525M Deal

Patent Awarded for Safer Cancer Drug Delivery

Chemotherapy vials

A pharmaceutical R&D company is receiving a patent for its process that encapsulates and better targets chemotherapy drugs for cancer patients. . . . → Read More: Patent Awarded for Safer Cancer Drug Delivery

Gene Therapy Company Starts-Up, Gains $200M

Adeno-associated virus

A new company is underway commercializing research on gene therapies for inherited diseases, staked to an initial investment of $200 million. . . . → Read More: Gene Therapy Company Starts-Up, Gains $200M

Biotechs Partner on Gene-Edited Cancer Cell Therapies

Natural killer cell

Two biotechnology companies are collaborating on using the gene editing technique Crispr to create engineered immune-system cells to treat cancer. . . . → Read More: Biotechs Partner on Gene-Edited Cancer Cell Therapies

Gene Therapy Company Exploring DNA Circuit Technology

Circuit graphic

Spark Therapeutics, a developer of gene therapies, is gaining access to a technology that programs DNA sequences like integrated electronic circuits. . . . → Read More: Gene Therapy Company Exploring DNA Circuit Technology

Univ. Lab Develops, Licenses Sports Injury Implant

Pitcher Matt Grace

A medical device company now offers a synthetic tissue implant for torn rotator cuff, a common sports injury, designed at a Purdue University engineering lab. . . . → Read More: Univ. Lab Develops, Licenses Sports Injury Implant

AbbVie Licenses Engineered Crispr Cell Process

Drug maker AbbVie is acquiring a technology using the gene-editing process Crispr to produce new off-the-shelf engineered T-cells as disease therapies. . . . → Read More: AbbVie Licenses Engineered Crispr Cell Process

Cancer Immunotherapy Adapted for HIV

T-cell infected by HIV

A biotechnology company is adapting and licensing its immunotherapy process, originally designed for cancer, as a cure for HIV infections. . . . → Read More: Cancer Immunotherapy Adapted for HIV

Institutions Join Global Health Breakthrough Network

Networked earth

Wellcome Leap aims to establish a model for faster design and development of health breakthroughs, beginning with elimination of administrative obstacles. . . . → Read More: Institutions Join Global Health Breakthrough Network